Principal Financial Group Inc. Raises Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Principal Financial Group Inc. grew its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 25.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 120,008 shares of the medical instruments supplier’s stock after purchasing an additional 24,047 shares during the period. Principal Financial Group Inc. owned about 0.30% of AngioDynamics worth $1,127,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ANGO. Bank of New York Mellon Corp increased its stake in AngioDynamics by 3.2% in the fourth quarter. Bank of New York Mellon Corp now owns 122,676 shares of the medical instruments supplier’s stock valued at $1,124,000 after purchasing an additional 3,815 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in AngioDynamics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier’s stock worth $3,014,000 after purchasing an additional 2,270 shares during the last quarter. Intech Investment Management LLC acquired a new position in AngioDynamics in the 4th quarter valued at about $152,000. American Century Companies Inc. lifted its stake in shares of AngioDynamics by 22.1% in the 4th quarter. American Century Companies Inc. now owns 67,942 shares of the medical instruments supplier’s stock worth $622,000 after acquiring an additional 12,306 shares during the period. Finally, Segall Bryant & Hamill LLC increased its stake in shares of AngioDynamics by 55.3% during the fourth quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock worth $12,963,000 after acquiring an additional 503,713 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of AngioDynamics in a report on Wednesday. Canaccord Genuity Group set a $17.00 price target on AngioDynamics and gave the stock a “buy” rating in a research note on Wednesday. Finally, Lake Street Capital initiated coverage on shares of AngioDynamics in a research note on Wednesday. They issued a “buy” rating and a $24.00 target price for the company.

AngioDynamics Stock Down 0.6%

NASDAQ ANGO opened at $8.69 on Friday. The business has a 50 day moving average price of $9.86 and a two-hundred day moving average price of $10.06. AngioDynamics, Inc. has a fifty-two week low of $5.83 and a fifty-two week high of $13.50. The stock has a market cap of $352.90 million, a PE ratio of -10.47 and a beta of 0.60.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The business had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. During the same period in the prior year, the company posted ($0.06) EPS. The business’s revenue was up 13.0% compared to the same quarter last year. Sell-side analysts anticipate that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.